Investor's Business Daily on MSN
Arrowhead says its gene silencer doubled Zepbound's weight loss
Arrowhead PharmaceuticalsARWR said Tuesday its gene-silencing approach delivered almost double the amount of weight loss over ...
Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...
9hon MSN
Zepbound boost gets a lift from Arrowhead’s drug. The question is whether patients will pay.
Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and ...
Arrowhead Pharmaceuticals said Tuesday that its gene-silencing candidates helped people with obesity lose fat.
Arrowhead Pharma (ARWR) stock jumps as obesity drug ARO-INHBE doubles weight loss with Eli Lilly’s (LLY) GLP-1 therapy, ...
Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback